Conference Description:

13th International Conference on Biosimilars and Biologics
About conference
Biosimilars Conferences is inviting you to attend Biosimilars Congress 2019 on March 18-19, 2019 Amsterdam | Netherlands. The topic of the current year's gathering is Biosimilars & Biologics: Present Scenario & Future Prospects which will give a worldwide stage to talk of present and future of Biosimilars.

Biosimilars Congress 2019 gathering will empower us to continue plunging further into both the examination of Biosimilar change and the business necessities for associations.

The Organizing Committee is satisfied to welcome you to attend the "13th International Conference on Biosimilars and Biologics", one of its astonishing Pharmaceutical gatherings to be held in March 18-19 | 2019 in Amsterdam, Netherlands.

Our Conferences on Biosimilars joins scientists, authorities and CROs from around the world. The Biosimilars Congress 2019 experiences an exponential improvement over the coming couple of years. Various Biologics things are affecting their passage in the pharma to publicize and experiencing a striking climb in their utilization over the standard remedies.

At Biosimilars 2019 meet your planned intrigue bunches from around the world focused on getting some answers concerning Biosimilars and Biologics. This gathering would be your single most obvious opportunity to accomplish the greatest accumulation of individuals from the Biosimilars and Biologics gathering.

Biosimilars Congress 2018 gather was a hit we could get learning from two specific gathering one that surpassed desires in the deliberate and collecting end and one that surpassed desires in the business and key end.

This year’s flagship event will gather top Europe Associations, Societies, Companies, Laboratories, Global regulators, Officials, Healthcare Actors as well as Industry leaders, to foster open exchange and debate on the role of the Biosimilars and Biologics sector in “Biosimilars Congress 2019 : Present Scenario & Future Prospects”.

Why to Attend?
Biosimilars Congress 2019 gives a complete 360-degree overview on Biosimilars and Biologics: Present scenario & Future prospects. Participants will leave the conference with a wealth of new information and an expanded network of contacts.

The Biosimilar is a lucrative sector owing to recent regulatory approvals and increasing opportunities. Biosimilars and Biologics are at different stages of evolution across the globe. Developing a Biosimilars demands huge investment, technical capabilities and clinical trial expertise. In order to unlock the Biosimilars potential, the industry will entail focused strategies along the whole value chain, from optimizing the clinical development program to commercialization.

Biosimilars Conferences developments are maintaining their momentum and the 2019 Biosimilars Conferences programme delves into strategic discussions regarding:

Market and regulatory developments in the Europe and globally, enlightened by the perspective of healthcare professionals and patients experiences
Pharmacovigilance and clinical practice - what can be learned from the emerging data?
The impact of Biosimilars on the competitive landscape of biological products
Developing Biosimilars & Biobetters
Innovator Pharmaceutical Products of Biosimilars
Current Challenges and Research trends in Biosimilars & Biologics
Biosimilars: Pharmacovigilance and Safety
BCS & IVIVC Based Biowaivers
Biopharmaceutical
Biological Medicines
Bioequivalence Assessment
Developing Biosimilars & Biobetters
Generics and Biosimilars: Industrial Strategy
Globalization of Biosimilars
GMP, GCP, QC & R&D
Innovation and Technology for Biosimilar Development
Intellectual Property Rights
Novel Drug Delivery Technologies
Pharmacology and Drug Development
Plant Produced Biosimilars
Protein Biotherapeutics and Biosimilars
Regulatory Approach for Biosimilars

Learning objectives

Update the participants on the current knowledge including regulatory and scientific thinking
Deal with regulatory requirements, scientific and operational challenges
Exchange experiences and discuss hot topics with experts
Frame the current issues and create dialogue

Sessions and Tracks
Track-1: Developing Biosimilars & Biobetters

Biosimilars are surmounting pharmaceutical business division from most recent three decades and deals appear to extend coherently. Advances in the biotechnology prompt to change and exposure of new natural items (Biosimilars) to treat diverse life-debilitating illnesses. Biosimilars are organic medications that are conveyed after expiry of the patent of affirmed pioneer and include Hatch-Waxman act is the amendment to Federal, Food, Drug and Cosmetics act which established the modern system of approval of generics through Abbreviated New Drug Applications (ANDAs).

Sub Tracks:

Key Aspects in Technical Development
Analysis of the Biosimilar Development Pipeline
Legal Issues and Implementation of the BPCI Act

Track-2: Intellectual Property Rights

The safeguarding of product trade secret, its formulations and other process parameters by law is usually covered by IPR. It includes those as patents, copyrights, industrial design rights, trademarks etc. IPR is of prime importance in the field of Biologics and Biosimilars. Most scientist and industries tend to retain their monopoly business by exercising the IPR. Currently, the US provides 12 years of exclusivity for new biological products under the Biologics Price Competition and Innovation Act (BPCIA).The provision providing 12 years exclusivity was buried inside the 20,000-page healthcare law. Eight years of exclusivity would keep biologic medicines out of the hands of many who need them. Prices frequently exceed $100,000.

Sub Tracks:

Pharma patent scenario
Criteria for patentability and patent claims
Critical research issues
Patentable subject matter
Recent patent disputes and litigations

Track-3: Innovative Approaches for Biosimilars

A biosimilar is an organic item very like an affirmed natural item, known as a kind of perspective item, with no clinically significant contrasts as far as wellbeing and viability. In the U.S., if a natural compound exhibits practically identical information to a U.S. Nourishment and Drug Administration (FDA)- authorized item from expository, preclinical and clinical reviews, it will be acknowledged as a biosimilar after termination of trend-setter licenses through a curtailed course. Tradable natural items are likewise Biosimilars, however should meet extra criteria to coordinate the reference item. Interchangeable can be substituted for the reference item without a medicine from a social insurance supplier.

Sub Tracks:

Biosimilar Product Reimbursement and Pricing
Biosimilar Regulatory Updates and Legal Implications
Biosimilar Market Access and Commercialization

Track-4: Regulatory Advances in Biosimilars

An FDA analysis of drug prices from 1999 to 2004 found that the discount from generic competition was just 6 percent with one generic competitor, but jumps to 48 percent with two generic competitors, 56 percent with three, 61 percent with four and 67 percent with five generic producers in a market. Within two years of the expiration of the patent for the popular drug Zantac in mid-1997, generic versions accounted for 90 percent of the treatment’s total sales, and the price for patients was about 10 percent of its pre-generic price. European patents on biologic treatments began to expire in 2000, and in April 2006, Sandoz and Biopartners received EMEA approval for the first European Biogenerics, two products containing human growth hormone.

Sub Tracks:

Biosimilars regulation
BLA filing for Biosimilars
Regulatory prospects of BRIC countries
Aparadigm of traditional generics to Biosimilars
Biowaiver approval for Biosimilars
Generic Biosimilars
Regulatory Prospects in BRIC countries

Track-5: Legal Issues and BPCI Act

The legal issues pertaining to the follow-on-Biologics and Biosimilars are one of the most aspects that require an open discussion. Before the actual advent of Biosimilars to the market legal issues have risen in numbers in their developmental stages. Renowned organizations have filed cases against each other two claim their rights and for other legal allegations related to the products. This track is dedicated to discussion of all such cases which has been argued in the court of law. By 2002, the FDA had approved 36 new Biologics, followed by 37 more in 2003, another 40 in 2004 and 39 more in 2005. By 2006, the leading category of biologic treatment, the red blood cell enhancer recombinant erythropoietin (EPO), generated $14 billion in sales revenues, or 40 percent more than the best-selling traditional pharmaceutical, Lipitor. More than 300 therapeutic antibodies currently are in clinical development and trials, compared to just 13 that already are widely available due to legal issues.

Sub Tracks:

Implementation of the BPCI Act
Patent protection and infringement issues
Patent negotiation and litigation phase
Market exclusivities

Track-6: Current Agency Expectations for Approval for Biosimilars

Biosimilars are a relatively new subset of biopharmaceuticals, with the biotechnology industry finally maturing such that off-patent generic-type products increasingly will be entering major markets. So far, more than 20 Biosimilars for a limited number of reference products have been approved in major markets, primarily the European Union. Only two products have been formally approved as Biosimilars in the United States. The parent field of biopharmaceuticals itself continues to exhibit a poor supporting infrastructure of information resources. Those biopharmaceutical and biosimilar information resources that do exist generally are limited in number, diversity, and sophistication.

Sub Tracks

Drug safety of Biosimilars products
Regulatory aspects
Regulatory affairs and IPR of Biosimilars products

Track-7: Novel Drug Delivery Technologies

Biosimilar Engineers and their outsourcing accomplices must know about the picked nation's administrative scene, and have broad information of any current Biosimilar endorsement pathway and the most recent administrative organization rules. Furnishing administrative experts with endorsements of investigation (CoA) for a U.S. - advertised comparator could challenge. As opposed to European practice, U.S. makers tend not to make CoAs accessible to parties required in the production network or bolster the improvement of a contender by discharging CoAs for clumps acquired for clinical trials. Giving family proclamations to the reference item more often than not is acknowledged as an option.

Sub Tracks:

Product Similarity for Biosimilars & Analytical Challenges
Role of Medical Affairs in Biosimilars
Regulatory strategy for generics and Biosimilars

Track-8: USFDA Approved Biosimilars

The European regulatory authorities led with a specially adapted approval procedure to authorize subsequent versions of previously approved Biologics, termed "similar biological medicinal products", or Biosimilars. This procedure is based on a thorough demonstration of "comparability" of the "similar" product to an existing approved product. In the United States, the Food and Drug Administration (FDA) held that new legislation was required to enable them to approve Biosimilars to those Biologics originally approved through the PHS Act pathway. The FDA gained the authority to approve Biosimilars (including interchangeable that are substitutable with their reference product) as part of the Patient Protection and Affordable Care Act signed by President Obama on March 23, 2010.

Sub Tracks:

Biosimilar and Interchangeable Products
Biosimilar Development, Review, and Approval
Prescribing Biosimilar and Interchangeable Products
Biosimilar Product Information
Industry Information and Guidance

Track-9: Consequences of Brexit on Biosimilars

With Europe that paved way to the uptake of Biosimilars over a decade ago, the consequences of Brexit would be potentially harder on UK. Presently UK is no more bound to follow the guidelines of EMA. Also research grants from Innovative Medicines Initiative and Horizon 2020 would no more be available to UK. All the same, EMA has its headquarters in London, UK. The thus arising complications would definitely have certain consequences on the Biosimilars scenario in UK and EU.

Sub Tracks:

Brexit- Pros and Cons to European pharma market
Post Brexit changes in Biosimilars regulation in UK
Fate of Biosimilars clinical trials in UK
Research funding from European organizations to UK based research laboratories

Track-10: Biosimilars Market Strategy

Effective management of a current good manufacturing practice (GMP) facility requires a strict eye on all those factors. This also includes Bioanalytical methods, Formulation, Bioassay for comparability and potency testing, GMP protein analysis, LC/MS analysis for discovery, preclinical, and clinical programs. Analysis of Biosimilars and Biologics forms to be one of the most important aspects towards the Biologics and Biosimilar development process. On average, facilities outsource 32% of their analytical testing/bioassays (up from 28%) meaning that close to one-third of analytical testing is estimated to be outsourced by the industry. The market for Biosimilars follow-on-Biologics is expected to grow at an exponential rate for next decade with the expiry of most patented drugs by 2020.The market in the APAC region for Biosimilars reached $605 million in 2010 and $683 million in 2011. The market is expected to reach $1.1 billion by 2016, a CAGR of 10.3%. The market in the United States for Biosimilars reached $507 million in 2010 and $1.1 billion in 2011. The market is expected to reach $1.3 billion by 2016, a CAGR of 4.1%.

SubTracks:

Biosimilar bioanalytical methods
Biosimilar Formulation
Bioassay for comparability and Potency Testing
Biosimilar GMP protein analysis
Biosimilar lc/ms analysis for discovery, preclinical, and clinical programs
Biosimilar Electrophoresis
Biosimilar multimodal techniques
Biosimilars companies

Track-11: Emerging Biosimilars in Therapeutics

Biosimilars Market is experiencing a growth at an exponential rate. Presently around 700 Biologics are making progress in the research pipelines of nearly 250 Biopharma companies. Biosimilar insulins have already started revolutionizing the future drug development in the realm of diabetology. Biosimilars of Adalimumab, Etanercept, Rituximab, Peg-Filgrastim, Trastuzumab are expected to hit the market soon. Biosimilar of Humatrope, biosimilar of Eprex, biosimilar of Neupogen, biosimilar of Remicade have already been enjoying a greater market share in Europe than the reference product itself. The proportion of different Biosimilars that reached market are Low Molecular Weight Heparins 44%, Epoetins 19%, HGH 11%, G-CSFs 7%, Interferons 6%, Insulins 5%, Others 8%.

SubTracks:

Biologics in cancer
Biologics for psoriasis
Biosimilar monoclonal antibodies
Recombinant therapeutic proteins
Insulin Biosimilars
Biologics in autoimmune disease

Track-12: Challenges in Biosimilars

The generic version of Biologicals- “Biosimilars” is the new buzz word in the world of pharmaceutical industry. Biosimilars are highly similar to their licensed reference product not withstanding minor differences as excipients in the formulation; also there are no remarkable differences between the Biologicals and the reference product in terms of safety, purity, and potency. However, there are certain challenges in way of its development and receiving a green signal for launching into the market. Newer Biologics also are targeting widespread diseases, with profound implications: a drug that costs $20,000 per year that is useful for 1 person in 100,000 has much less effect on a health plan’s cost structure than a $5,000-per-year drug that is useful for 1 in 100 people.

SubTracks:

Current concepts of drugs and Biologics
Unique considerations for Biologics
Early clinical development essentials
Late clinical development essentials
Drug safety essentials
Cancer Therapeutics
Comparability for Biologics
Quality by Design for Biologics and Biosimilars

Track-13: Chemical and Analytical Strategies for Biosimilars

Management of cGMP facility calls for a strict monitoring all factors including analytical strategies, formulation procedures, packaging etc. For biologic products establishing comparability and interchangeability is a big hurdle. For this purpose employment of suitable analytical approach, bioassay, protein analysis, potency testing, safety assurances are highly important. LC/MS analysis for biologic products, characterization of Biologics, peptide mapping, Isoelectric Focusing and Capillary Isoelectric Focusing, SDS-PAGE, Thermal Analysis, Particulate Matter Analysis, Thermogravimetric Analysis are some methods commonly used for analysis of Biologics and Biosimilars products. On average, facilities outsource 32% of their analytical testing/bioassays (up from 28%) meaning that close to one-third of analytical testing is estimated to be outsourced by the industry.

While small changes in these parameters can impact the various chemical permutations for a given biotherapeutic, innovators can, under certain circumstances, change the host cell, fermentation process, purification process, and even manufacturing site, but the product can be validated without undertaking a complete new product development review.

SubTracks:

Biosimilars multimodal techniques
Biosimilars bioanalytical methods
Bioassay for comparability and potency testing
Biosimilars LC/MS analysis for discovery, preclinical and clinical programs
Biosimilars GMP protein analysis
Biosimilars electrophoresis

Track-14: Bioequivalence Assessment

Bioequivalence focuses on the equivalence of release of the active pharmaceutical ingredient from the pharmaceutical product and its subsequent absorption into the systemic circulation. This session has utmost importance in context to the fact that only a suitably bioequivalent drug candidate that conforms the results in all respects to the original licensed product can be called as biosimilar drug. Of all attempts towards developing a follow on Biologics or a biosimilar drug the main detection point stands at the Bioequivalence Assessment. Once the bioequivalence has been obtained it can be 70% ascertained the drug qualifies to be a suitable Biologics or Biosimilars.

Sub Tracks:

Strategies for the bioequivalence assessment of topical dosage forms
Bioequivalence assessment of respiratory dosage forms
Bioequivalence approaches for transdermal dosage forms
Evaluation of highly variable drugs and drug products

Track-15: Biological Medicines

Biological Medicine works with the biology of the body and its natural healing capabilities as well as the spiritual, emotional and physical aspects of disease. Disease means that the body’s regulation is not working properly and needs to be brought back into its natural dynamic state where the immune system is in full regulation. It therefore looks for root causes for the presenting symptoms of disease the underlying factors causing a person to present with a certain illness. These root causes may consist of several factors which have built up over time and can include; diet, food allergies, intestinal disturbances, family history, stress, environmental factors, heavy metals, dental problems, hyperacidity, trauma, exposure to bacteria or viruses or electromagnetic disturbances.

Sub Tracks:

Advances in Biological products
Biological drugs
Generic Biological drugs
Biotechnology medicinal products for different drugs
Future of next generation Biosimilars
Biopharmaceuticals development

Track-16: Biosimilars Approval to Biogenerics in Clinical Practice

Biological medicines are much more structurally complex and extremely sensitive to manufacturing conditions and therefore more difficult to characterize and produce than small molecule drugs. Even minor changes in manufacturing may lead to significant variations of the cellular systems used for biological production, as well as to differences in the structure, stability, or other quality aspects of the end product, all of which have the potential to affect tolerability and/or efficacy and increase the risk of immune responses. Owing to these issues, specific regulatory guidance on Biosimilars is continuously evolving, and there is some disagreement on which studies need to be implemented to approve a Biosimilars. According to current literature, the following points on Biosimilars deserve consideration: Biosimilars development is characterized by global harmonization, although several not fully answered questions remain regarding extrapolation of indications, switching or interchange ability, and tolerability; in patients with rheumatic diseases, the tolerability and efficacy of Biosimilars in clinical practice remain to be established; several medical and patient associations have published position papers on Biosimilars requesting that safety, efficacy, and traceability be carefully considered; long-term post marketing studies should be implemented to allow physicians to gain confidence in Biosimilars.

SubTracks:

Biotechnologic drug
Monoclonal antibody
Fusion protein
Biologic drug
Anti–tumor necrosis factor

Track-17: Biopharmaceutical

Biopharmaceutical are also called medical product these Biopharmaceuticals includes blood, blood components, gene therapy, Recombinant therapeutic protein. Biopharmaceutical informatics is used in information technology, molecular modeling and biologic drug development. Development of databases containing the experimental data on biophysical stability, safety along with molecular sequence

Sub Tracks:

Applications of computation in Biologic drug development
Protein sequence-structural contexts and degradation reaction mechanisms
Creation of databases and data mining
Pre-clinical immunogenicity risk assessment of Biotherapeutics
Monoclonal antibodies (Various)
Blood components
Vaccines
Biopharmaceutical Research

Track-18: BCS & IVIVC Based Biowaivers

The objective of this track is to suggest the Biowaivers potential of Biopharmaceutical classification system which is known to increase the solubility, dissolution, oral absorption of water insoluble drugs. Biopharmaceutics Classification System and Invitro and Invivo classification discusses about ADME pathways of different drugs. This track also includes BCS biowaivers, in vitro diffusion cells for dissolution testing in formulation development, in vitro preclinical ADME/BCS testing. Until in vitro in vivo correlation achieves the required degree, the Biosimilar drug will not be able to meet the needs of the original drug candidate. Hence the proportion of BCS and IVIVC based biowaivers are fairly low ~0.5-1% of total pharmaceutical products.

Sub Tracks:

BCS biowaivers
Preclinical and clinical testing for oral drug delivery
Waiver for In vivo Bioavailability or Bioequivalence
Consideration of Biowaiver extensions for BCS class III drugs
In vitro diffusion cells for dissolution testing in formulation development
Dissolution testing in drug formulation
In vitro preclinical ADME/BCS testing
In vitro drug product research

Track-19: Pharmacovigilance Challenges and Safety

Biosimilar guidelines for Pharmacovigilance practice and Pharmacoepidemiology are the points that shall be laid emphasis in this session. U.S. average annual spending growth from 2002 to 2007 was 16% for Biologics, compared with 3.7% for drugs. In same proportion Pharmacovigilance for Biosimilars has been comparatively more than other pharmaceutical products. Biosimilars are interlinked with FDA activities that have as of now been declared to incorporate upgraded following and follow-up of post market issues, arranged changes in AERS, and pilots of new post advertise medicate observing systems. Current difficulties in Pharmacovigilance, adverse medication responses with pharmaceutical items, Biosimilar rules for Pharmacovigilance practice and pharmacoepidemiology are the focuses that should be laid accentuation in this session.

SubTracks:

Current problems in Pharmacovigilance
Adverse drug reactions with Pharmaceutical products
Detection and evaluation of drug safety signals
Improve Pharmacovigilance through Patient and Provider Education
Regulatory updates and key drivers for registration approvals in US, EU and China
Regulatory requirement for Biosimilar IND filing in the US
Role of Pharma industries in the improvement of Pharmacovigilance system

Track-20: Generic Biosimilars: Industrial Strategy

The "Generic Drugs Market: 2015 - 2030 - Opportunities, Challenges, Strategies & Forecasts" report presents an in-depth assessment of the generic drugs and Analysis of key therapeutic areas and leading generic drugs pufecosystem including technology, economics, key trends, market drivers, challenges, investment potential, regulatory landscape, leading therapies, Pharmaceutical Industry opportunities, future road map, Following key trends, market drivers, challenges, Analysis of key therapeutic areas and leading generic trends ,value chain, ecosystem player profiles and strategies and Regulatory landscape of global trends throughout the globe The report also presents market size forecasts for generic drugs from 2017 through to 2030. The forecasts are segmented for over 10 therapeutic areas, 3 brand classifications, 5 regions and 25 leading countries.

Sub Tracks:

Clinical development strategies for Biosimilars
Advances in Biosimilar Production & Technologies
Scale Up of Biosimilars
Business Development in biosimilar
Major market trends & Featured regional market trends

Track-21: Formulation Strategies for Follow-on Biologics

For this rapidly growing industry sector, little consensus or authoritative information is available yet regarding how and where biosimilar products will be produced. The future of their manufacturing is still up in the air. Much discussion among experts has focused on a dramatic up-tick in Contract Manufacturing Organizations (CMOs) involvement with process development projects and clinical-scale manufacturing for Biosimilars. None have really set up commercial-scale projects (yet), however. Many such companies are publicly discussing large-scale partnerships for production in India and elsewhere in Asia. On the other hand, some Biosimilars sponsors are establishing relationships with smaller biotech CMOs that have demonstrated expertise in efficiency or lower-cost business models

Sub Tracks

Multiproduct or dedicated single product plants
Major markets or developing countries
Single-use, stainless steel or hybrid
Continuous bioprocessing

Track-22: Pharmacology and Drug Development

Pharmacology is the branch of solution and science worried with the investigation of medication action where a medication can be comprehensively characterized as any man-made, characteristic, or endogenous (from inside body) particle which applies a biochemical and additionally physiological impact on the cell, tissue, organ, or living being (once in a while the word Pharmacon is utilized as a term to envelop these endogenous and exogenous bioactive species). Sedate improvement is the way toward conveying another pharmaceutical medication to the market once a lead compound has been distinguished through the procedure of medication revelation. It incorporates pre-clinical research on microorganisms and creatures, petitioning for administrative status, for example, by means of the United States Food and Drug Administration for an investigational new generic medication to start clinical trials on people, and may incorporate the progression of acquiring administrative endorsement with another medication application to showcase the medications and Increase Global Pharma Market

Sub Tracks:

Clinical pharmacology and Drug addictions
Characterization of biologically active compounds
Recent advancements in research and developments
Recent advances in computer aided drug design
Novel Approaches in drug discovery

Track-23: Globalization of Biosimilars

Globalization of Biosimilars is about the generic drugs impact on Global Biosimilar market, Cost and risk management, adopting innovative mechanisms such as risk-sharing arrangement, European market for Biosimilars. A growing global market for Biosimilars is gaining momentum in response to the expiration of patents for a number of key Biologics and consumer demand to reduce treatment costs. Thus, according to Research and Markets, the global biosimilar market, valued at $2 billion in 2012 is projected to reach $19.4 billion by 2018.

Sub Tracks:

Global impact of Biosimilars over generics
Economic aspect towards Biosimilars
Biosimilars in global market
Investment and returns on Biosimilars
Cost and risk management
Adopting innovative mechanisms such as risk-sharing arrangement
European market for Biosimilars
Global P&R models for the Biosimilars and generics market

Track-24: Protein Biotherapeutics and Biosimilars

Biotherapeutics more often than not alludes to helpful materials created utilizing organic means, including recombinant DNA innovation. Biotherapeutics are fundamentally operators, used to treat and maintain a strategic distance from human malady by interrelating with the microbial environment of the host. Biotherapeutics can target particular particles inside the human body, and have a decent reputation with patient wellbeing. Fabricating biotherapeutics is mind boggling, as they are bigger mixes in both size and structure, and can be touchy to ecological conditions.

Sub Tracks:

Advancements in Biotherapeutics
Biotech and Biosimilar Products
Antibody based therapeutics
Therapeutic Antibodies and Fc Fusion Proteins

Track-25: Plant Produced Biosimilars

Biosimilar products are also produced from plants. Plants are the richest store house of diverse class of phytochemicals. Production of Biosimilar products in tobacco plants is on the verge of completion of the first step in their research. These also includes Transgenic plants, Post translational genetics, Fermentation culture, Molecular farming. For biosimilar manufacturers this session has the potential to bring up new avenues in their product range. Pharmacognosy researchers would find this track highly interesting and informative towards their research work. Proportion of plant produced Biosimilars are comparably low. However, an increased level of plant sourced Biologics ~25% is owned to be seen in the market. Especially Biologics derived from the plant sources are expected to occupy about more than 20% of all Biologics.

Sub Tracks:

Transgenic plants
Post translational genetics
Fermentation culture
Molecular farming

AGENDA

Day 1
ProgramOutline
Registration 08:00-09:00
InauguralSession 09:00-09:15 Keynote/
Plenary talks
Keynote/Plenarytalk:1(Academia) 09:15-09:45
Keynote/Plenarytalk:2(Industry) 09:45-10:15
Keynote/Plenarytalk:3 (Exhibitor/Sponsorslot) 10:15-10:45
Coffee break/Networking 10:45-11:00
Oral Presentations andPanelDiscussions 11:00-13:00
Lunch break/Networking 13:00-14:00
Sponsor/Exhibitorspresentations 14:00-14:30
Oral Presentations andPanelDiscussions 14:30-16:00
Coffee break/Networking 16:00-16:15
Workshops/YRF/Posters/VideoPresentatio ns 16:15-17:00
Sponsor/Exhibitorspresentations 17:00-17:30
CertificateDistribution&Day1conclusion Remarks 17:30-18:00
ProgramOutline

Day-2
Registration 08:00-09:00
InauguralSession 09:00-09:15 Keynote/ Plenary talks
Keynote/Plenary talk:1(Academia/Industry) 09:15-09:45
Keynote/Plenarytalk:2 (Exhibitor/Sponsorslot) 09:45-10:15
Workshops/Symposium 10:15-10:45
Coffee break/Networking 10:45-11:00
Oral Presentations andPanelDiscussions 11:00-13:00
Lunch break/Networking 13:00-14:00
Sponsor/Exhibitorspresentations 14:00-14:30
Oral Presentations andPanelDiscussions 14:30-16:00
Coffee break/Networking 16:00-16:15
YRF/Posters/VideoPresentations 16:15-17:00
CertificateDistribution&Day2conclusion Remarks 17:00-17:15

Please contact the event manager Marilyn (marilyn.b.turner(at)nyeventslist.com ) below for:
- Multiple participant discounts
- Price quotations or visa invitation letters
- Payment by alternate channels (PayPal, check, Western Union, wire transfers etc)
- Event sponsorships